

# ForPatients

*by Roche*

Hepatocellular Carcinoma (HCC)

## A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Hepatocellular Carcinoma

**Trial Status**

Active, not recruiting

**Trial Runs In**

2 Countries

**Trial Identifier**

NCT04712643 ML42612

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

This study will evaluate the efficacy and safety of atezolizumab plus bevacizumab combined with on-demand TACE compared to on-demand TACE alone in participants with hepatocellular carcinoma who are at high risk of poorer outcome following TACE treatment.

**Hoffmann-La Roche**

Sponsor

**Phase 3**

Phase

---

**NCT04712643 ML42612**

Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**

All

**Age**

**>=18 Years**

**Healthy Volunteers**

No

---